
Italfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeting Therapeutics for Neuromuscular, Fibrotic, and Rare Diseases
Italfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeting Therapeutics for Neuromuscular, Fibrotic, and Rare Diseases Italfarmaco S.p.A., a global pharmaceutical company with established expertise in histone deacetylase biology and therapeutic development, and VeriSIM Life, an AI-enabled drug discovery and…













